Literature DB >> 7866549

High-performance liquid chromatographic assay of human red blood cell thiopurine methyltransferase activity.

L Lennard1, H J Singleton.   

Abstract

An assay is described for the determination of red blood cell (RBC) thiopurine methyltransferase (TPMT) activity. TPMT S-methylates the antileukaemic drugs 6-mercaptopurine (6-MP) and 6-thioguanine and enzyme activity is inherited as a genetic trait. The assay is based on the TPMT-catalysed conversion of 6-MP to 6-methylmercaptopurine (methyl-MP) with non-radioactive S-adenosyl-L-methionine as the methyl donor. The methyl-MP metabolite is extracted into toluene as a phenyl-mercury adduct and back-extracted into 0.1 M HCl. Methyl-MP is quantitated by reversed-phase high-performance liquid chromatography (HPLC) with ultraviolet detection using a C18 Resolve cartridge and a mobile phase of methanol-water (20:80, v/v) with 100 mM triethylamine adjusted to pH 3.2 with orthophosphoric acid. There was a strong correlation between the HPLC assay and the established radiochemical assay (P < 0.0001). TPMT activities were measured by both methods in a population study of 111 children. There was no significant difference between the two frequency distribution histograms (P > 0.6).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7866549     DOI: 10.1016/0378-4347(94)00327-0

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  12 in total

Review 1.  Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease.

Authors:  Kara Bradford; David Q Shih
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

2.  Human thiopurine methyltransferase activity varies with red blood cell age.

Authors:  L Lennard; T S Chew; J S Lilleyman
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

Review 3.  Therapeutic drug monitoring of antimetabolic cytotoxic drugs.

Authors:  L Lennard
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

4.  6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity.

Authors:  C Cuffari; Y Théorêt; S Latour; G Seidman
Journal:  Gut       Date:  1996-09       Impact factor: 23.059

5.  Phenotyping and genotyping study of thiopurine S-methyltransferase in healthy Chinese children: a comparison of Han and Yao ethnic groups.

Authors:  Jian-ping Zhang; Yong-yuan Guan; Jue-heng Wu; An-long Xu; Shufeng Zhou; Min Huang
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

6.  Implementation of TPMT testing.

Authors:  Lynne Lennard
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

7.  Thiopurine S-methyltransferase testing for averting drug toxicity in patients receiving thiopurines: a systematic review.

Authors:  Lilla M Roy; Richard M Zur; Elizabeth Uleryk; Chris Carew; Shinya Ito; Wendy J Ungar
Journal:  Pharmacogenomics       Date:  2016-03-29       Impact factor: 2.533

8.  Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age.

Authors:  Catherine Ganiere-Monteil; Yves Medard; Corinne Lejus; Béatrice Bruneau; Alain Pineau; Odile Fenneteau; Michel Bourin; Evelyne Jacqz-Aigrain
Journal:  Eur J Clin Pharmacol       Date:  2004-03-12       Impact factor: 2.953

9.  Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes.

Authors:  Alice Matimba; Fang Li; Alina Livshits; Cher S Cartwright; Stephen Scully; Brooke L Fridley; Gregory Jenkins; Anthony Batzler; Liewei Wang; Richard Weinshilboum; Lynne Lennard
Journal:  Pharmacogenomics       Date:  2014-03       Impact factor: 2.533

10.  Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.

Authors:  Lynne Lennard; Cher Suzanne Cartwright; Rachel Wade; Susan M Richards; Ajay Vora
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.